Pharming Net Income Applicable To Common Shares from 2010 to 2026

PHARM Stock  EUR 1.39  0.01  0.72%   
Pharming Group's Net Income Applicable To Common Shares is increasing over the years with slightly volatile fluctuation. Overall, Net Income Applicable To Common Shares is expected to go to about 16.5 M this year. Net Income Applicable To Common Shares is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Income Applicable To Common Shares  
First Reported
2016-12-31
Previous Quarter
-12.2 M
Current Value
1.3 M
Quarterly Volatility
12.6 M
 
Covid
 
Interest Hikes
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.3 M, Interest Expense of 6.6 M or Selling And Marketing Expenses of 7.8 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.82. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
This module can also supplement various Pharming Group Technical models . Check out the analysis of Pharming Group Correlation against competitors.
Analyzing Pharming Group's Net Income Applicable To Common Shares over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income Applicable To Common Shares has evolved provides context for assessing Pharming Group's current valuation and future prospects.

Latest Pharming Group's Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Pharming Group NV over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Pharming Group's Net Income Applicable To Common Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Pharming Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean1,341,380
Geometric Mean17,675,601
Coefficient Of Variation2,055
Mean Deviation21,232,710
Median13,674,000
Standard Deviation27,569,383
Sample Variance760.1T
Range116.8M
R-Value0.52
Mean Square Error588.2T
R-Squared0.27
Significance0.03
Slope2,860,617
Total Sum of Squares12161.1T

Pharming Net Income Applicable To Common Shares History

202616.5 M
202515.7 M
202213.7 M
202116 M
202037.7 M
201940.6 M
201825 M

About Pharming Group Financial Statements

Pharming Group stakeholders use historical fundamental indicators, such as Pharming Group's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharming Group's assets and liabilities are reflected in the revenues and expenses on Pharming Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharming Group NV. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Applicable To Common Shares15.7 M16.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Stock, refer to the following important reports:
Check out the analysis of Pharming Group Correlation against competitors.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
It's important to distinguish between Pharming Group's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharming Group should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pharming Group's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.